Literature DB >> 23157993

Metabolic syndrome: relative risk associated with post-traumatic stress disorder (PTSD) severity and antipsychotic medication use.

Pia S Heppner1, James B Lohr, Taylor P Kash, Hua Jin, Hongjun Wang, Dewleen G Baker.   

Abstract

BACKGROUND: In recent years, numerous lines of converging evidence have revealed an association between post-traumatic stress disorder (PTSD) and impaired physical health outcomes, including cardiovascular disease and metabolic syndrome. Although these findings have been interpreted as indicating a direct association of PTSD with metabolic syndrome and obesity, previous studies have not addressed the important confound of antipsychotic drug usage in this population. Second generation antipsychotic medications themselves are associated with metabolic syndrome and obesity, and it is unclear whether the common utilization of these drugs in PTSD may account for some if not all of the observed metabolic problems.
OBJECTIVE: The present study examined the relative contributions of PTSD severity and use of antipsychotic medications to risk of metabolic syndrome among veterans.
METHOD: Cross-sectional clinical data, including five factors representing metabolic syndrome, psychiatric diagnoses, and medications were gathered from 253 veterans enrolling in mental health services. We used a logistic regression model to measure the relative association of antipsychotic medication use and PTSD severity on risk of metabolic syndrome.
RESULTS: We found that antipsychotic medication usage was not uniquely associated with elevated risk of metabolic syndrome (Wald = 0.30, ns) when PTSD severity and other sociodemographic, psychiatric, and behavioral variables were accounted for. Furthermore, PTSD severity continued to be a significant and unique predictor of risk for metabolic syndrome (Wald = 4.04, p < 0.05).
CONCLUSIONS: These findings suggest that chronic and moderately severe PTSD, independent of antipsychotic medications, is associated with increased risk of metabolic syndrome. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23157993     DOI: 10.1016/j.psym.2012.05.005

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  14 in total

1.  Gender differences in antipsychotics prescribed to veterans with serious mental illness.

Authors:  Elana Schwartz; Melanie Charlotte; Eric Slade; Deborah Medoff; Lan Li; Lisa Dixon; Amy Kilbourne; Julie Kreyenbuhl
Journal:  Gen Hosp Psychiatry       Date:  2015-04-01       Impact factor: 3.238

2.  Stress- and PTSD-associated obesity and metabolic dysfunction: a growing problem requiring further research and novel treatments.

Authors:  Olivia M Farr; Denise M Sloan; Terence M Keane; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-08-28       Impact factor: 8.694

Review 3.  A Review of Posttraumatic Stress Disorder and Obesity: Exploring the Link.

Authors:  Kanaklakshmi Masodkar; Justine Johnson; Michael J Peterson
Journal:  Prim Care Companion CNS Disord       Date:  2016-01-07

4.  Longitudinal associations between post-traumatic stress disorder and metabolic syndrome severity.

Authors:  E J Wolf; M J Bovin; J D Green; K S Mitchell; T B Stoop; K M Barretto; C E Jackson; L O Lee; S C Fang; F Trachtenberg; R C Rosen; T M Keane; B P Marx
Journal:  Psychol Med       Date:  2016-04-18       Impact factor: 7.723

5.  Co-Occurrence of Posttraumatic Stress Disorder and Cardiovascular Disease Among Ethnic/Racial Groups in the United States.

Authors:  Carmen Vidal; Ruth Polo; Kiara Alvarez; Irene Falgas-Bague; Ye Wang; Benjamin Lê Cook; Margarita Alegría
Journal:  Psychosom Med       Date:  2018-09       Impact factor: 4.312

6.  Metabolic risk factors and posttraumatic stress disorder: the role of sleep in young, healthy adults.

Authors:  Lisa S Talbot; Madhu N Rao; Beth E Cohen; Anne Richards; Sabra S Inslicht; Aoife OʼDonovan; Shira Maguen; Thomas J Metzler; Thomas C Neylan
Journal:  Psychosom Med       Date:  2015-05       Impact factor: 4.312

7.  Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk.

Authors:  Satish A Eraly; Caroline M Nievergelt; Adam X Maihofer; Donald A Barkauskas; Nilima Biswas; Agorastos Agorastos; Daniel T O'Connor; Dewleen G Baker
Journal:  JAMA Psychiatry       Date:  2014-04       Impact factor: 21.596

8.  A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications.

Authors:  Julie Kreyenbuhl; Lisa B Dixon; Clayton H Brown; Deborah R Medoff; Elizabeth A Klingaman; Li Juan Fang; Stephanie Tapscott; Mary Brighid Walsh
Journal:  Community Ment Health J       Date:  2016-04-09

Review 9.  Metabolic, autonomic and immune markers for cardiovascular disease in posttraumatic stress disorder.

Authors:  Jeffrey L Kibler; Mischa Tursich; Mindy Ma; Lydia Malcolm; Rachel Greenbarg
Journal:  World J Cardiol       Date:  2014-06-26

10.  Posttraumatic Stress Disorder as a Catalyst for the Association Between Metabolic Syndrome and Reduced Cortical Thickness.

Authors:  Erika J Wolf; Naomi Sadeh; Elizabeth C Leritz; Mark W Logue; Tawni B Stoop; Regina McGlinchey; William Milberg; Mark W Miller
Journal:  Biol Psychiatry       Date:  2015-12-08       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.